Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 6;123(6):843-50.
doi: 10.1182/blood-2013-09-529008. Epub 2013 Nov 25.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Adele K Fielding  1 , Jacob M Rowe, Georgina Buck, Letizia Foroni, Gareth Gerrard, Mark R Litzow, Hillard Lazarus, Selina M Luger, David I Marks, Andrew K McMillan, Anthony V Moorman, Bella Patel, Elisabeth Paietta, Martin S Tallman, Anthony H Goldstone
Affiliations

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Adele K Fielding et al. Blood. .

Abstract

The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre-imatinib cohort). In 2003 imatinib was introduced as a single-agent course following induction (N = 86, late imatinib). In 2005 imatinib was added to the second phase of induction (N = 89, early imatinib). The complete remission (CR) rate was 92% in the imatinib cohort vs 82% in the preimatinib cohort (P = .004). At 4 years, the overall survival (OS) of all patients in the imatinib cohort was 38% vs 22% in the preimatinib cohort (P = .003). The magnitude of the difference between the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival (RFS) seen in univariate analysis was even greater in the multivariate analysis. In the preimatinib cohort, 31% of those starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imatinib cohort. A Cox multivariate analysis taking alloHSCT into account showed a modest additional benefit to imatinib (hazard ratio for EFS = 0.64, 95% confidence interval 0.44-0.93, P = .02), but no significant benefit for OS and RFS. Adding imatinib to standard therapy improves CR rate and long-term OS for adults with ALL. A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT. This trial was registered at clinicaltrials.gov as NCT00002514.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A flowchart of all patients entered into the Ph+ arm of UKALLXII/E2993.
Figure 2
Figure 2
Kaplan Meier plot of 10-year OS of all patients with Ph+ ALL by cohort. (A) Preimatinib vs imatinib. (B) Preimatinib vs late imatinib vs early imatinib.
Figure 3
Figure 3
A flowchart of postremission treatment. (A) Treatment received in the imatinib cohort. (B) Treatment received in the preimatinib cohort.
Figure 4
Figure 4
Kaplan Meier plot of 4-year OS in the imatinib cohort. Represents receipt of protocol myeloablative sibling/MUD alloHSCT, nonprotocol RIC alloHSCT, or no alloHSCT in patients who achieved CR on protocol and survived to day 84 (12 weeks), the earliest possible time of alloHSCT per protocol.
Figure 5
Figure 5
Kaplan Meier plot of 4-year OS in all patients with Ph+ ALL who did not receive alloHSCT, by preimatinib vs imatinib cohort.
See this image and copyright information in PMC

Comment in

References

    1. Moorman AV, Harrison CJ, Buck GA, et al. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189–3197. - PubMed
    1. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409–3417. - PubMed
    1. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408–1413. - PubMed
    1. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396–4407. - PubMed
    1. Towatari M, Yanada M, Usui N, et al. Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104(12):3507–3512. - PubMed

Publication types

MeSH terms

Associated data